Adapthealth sees $4.4 million in purchases by OEP entities

AdaptHealth reported Q4 2025 EPS of -$0.76 versus $0.36 expected (surprise -311.11%), while revenue was $846.3M vs $832.5M expected (+1.66%). Entities tied to One Equity Partners purchased a total of 447,827 shares across March 19-20 for $4.4M at weighted average prices ~$9.94 and ~$9.91, bringing holdings to 16,312,698 shares; the stock trades at $11.29, up ~9% over the past week and near a 52-week high of $11.75. RBC Capital maintained an Outperform rating with a $13.00 target and Leerink Partners kept Outperform but cut its target to $12.00, reflecting mixed analyst sentiment despite significant operating headwinds.

Analysis

The stock’s current setup favors an operational-improvement rerating rather than a pure growth story. If management can deliver on standardization and working-capital efficiency, expect 300–400bps of incremental margin expansion over 12–24 months driven by lower unit costs and fewer field service redundancies; that pathway creates optionality for a strategic sale or multiple expansion even if top-line growth moderates.

The largest near-term risks are payor/reimbursement decisions and cash-conversion dynamics. A negative CMS or large payor outcome can compress gross margins and force working-capital draws within a single quarter, while slower-than-expected execution on cost programs will push meaningful upside out beyond 12 months and make the name sensitive to rising rates and covenant scrutiny.

From a flow and positioning angle, reduced effective float and visible sponsor alignment (PE involvement) raise the probability of event-driven upside (co-invest or buyout) but also amplify short-term gamma — a modest print or guidance beat could trigger outsized moves. For that reason, execution-sensitive, time-boxed option structures and hedged equity exposure are the most economic ways to capture the rerating while protecting against binary reimbursement or execution shocks.

Key Decisions for Investors

• Long AHCO (6–12 month horizon): Buy a position sized to 2–3% of NAV with a 12-month target of +30–50% to capture operational re-rate; hedge with a protective 6-month put ~10–15% OTM sized at 25–33% of the equity notional to limit downside to ~10% net (cost ~3–6% of position).
• Options spread (event-driven, 3–9 months): Buy a 9–12 month AHCO call spread (buy ~+20% strike, sell ~+50% strike) to cap premium and target 3:1 upside if the market re-rates on improved margins or a strategic announcement; allocate no more than 1% NAV to this trade.
• Pair trade to neutralize market beta (3–6 months): Long AHCO / Short SMCI (equal-dollar) to isolate idiosyncratic rerating risk from broad tech-driven market moves — aim for small net delta, take profits if AHCO outperforms by >25% or if the pair diverges by >15% against you.
• Risk management trigger: Reduce position by half on any adverse CMS/payor announcement or if near-term cash conversion deteriorates (DSO/Inventory deterioration >15% vs Q/Q), and fully exit if sequential margin compression persists for two quarters.